ArticleBMJ open2026
Corneal and tear film immunology in anterior uveitis: protocol for a systematic review and meta-analysis.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionAnterior uveitis is an intraocular inflammatory condition that can lead to vision impairment without appropriate and timely treatment. Determining its aetiology can be difficult due to its heterogeneous clinical presentations, which challenges effective treatment. The primary aim of this systematic review is to comprehensively identify and synthesise evidence on the immunological features of anterior uveitis in the human cornea and tear film, as a foundation for considering the utility of such features as biomarkers for disease classification, prognosis and monitoring treatment responsiveness. METHODS AND ANALYSIS: Comprehensive electronic database searches will be performed in Ovid MEDLINE, Ovid Embase and the Cochrane Central Register of Controlled Trials (CENTRAL) without date restrictions. Two independent review authors will screen retrieved titles and abstracts in Covidence relative to predefined study eligibility criteria. Studies judged eligible or potentially eligible for inclusion will undergo full-text review using a similar method. Disagreements will be resolved by consensus. For each included study, risk of bias will be assessed using validated tools appropriate to the study design. Where sufficient and appropriate data are available, meta-analyses will be performed. For outcomes where a meta-analysis is not possible, a narrative synthesis will be provided. This review will be reported in accordance with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 2020 statement. ETHICS AND DISSEMINATION: Ethics approval is not applicable for this review as no original data will be collected. The results of this review are expected to be disseminated through a peer-reviewed publication and/or scientific conference presentations. PROSPERO REGISTRATION NUMBER: CRD420261339682.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.